<DOC>
	<DOCNO>NCT00154063</DOCNO>
	<brief_summary>This 22-week , prospective , randomize , double-blind , placebo-controlled , multicenter , parallel-group study include 4-week Baseline Phase begin 4-week single-blind placebo Safety Phase end study .</brief_summary>
	<brief_title>Efficacy Safety Study E2007 Migraine Prophylaxis</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>1 . Patients race , 18 65 year age inclusive . 2 . Patients history migraine ( without aura ) accord Headache Classification Committee IHS . Migraine attack onset age 50 present least 12 month . 3 . Patients 412 qualified migraine attack per month past three month prior Screening , well four week Baseline Phase eligible entry study . The interval two qualified migraine attack least 24 hour count distinct migraine attack . A qualified migraine attack without aura define headache last 472 hour ( untreated unsuccessfully treat ) successfully treat ( revise per Amendment 01 ) . This attack least two follow characteristic : unilateral location , pulsate quality , moderate severe intensity inhibits prohibits daily activity aggravation routine physical activity walk stair . In addition , least one follow symptom must present headache : nausea , vomit , photophobia phonophobia ( revise per Amendments 01 02 ) . A qualified migraine attack aura must fulfill criterion headache attack , plus associated aura define Migraine Criteria Headache Classification Committee International Headache Society . An aura alone require acute migraine treatment also consider migraine attack . 4 . Male female patient eligible enrollment . Females either nonchildbearing potential reason surgery , radiation , menopause ( one year post onset ) , childbearing potential practicing medically acceptable method contraception ( eg , abstinence , barrier method plus spermicide , IUD ) least one month study randomization two month end study , negative serum BhCG Screening . Pregnant and/or lactate female exclude . Those woman use hormonal contraceptive must also use additional approve method contraception ( eg , barrier method plus spermicide , IUD ) start Baseline Phase continue throughout entire study period . 5 . Patients Body Mass Index ( BMI ) 19 40 kg/m2 inclusive Screening . 6 . Patients willing participate provide write informed consent prior expose studyrelated procedure . 1 . Patients chronic daily headache define 14 headache day per month average three month prior Screening , 2 . Patients cluster headache trigeminal autonomic cephalalgia , primary headache ( except tensiontype headache ) secondary headache ( define accord Headache Classification Committee IHS 2004 ) , 3 . Patients history nonresponsive two class adequately conduct , prophylactic migraine treatment ( e.g. , beta blocker , calcium channel blocker , tricyclic , MAOIs , valproate ( divalproex ) , topiramate , gabapentin ) , 4 . Patients use follow medication describe : Use market triptans 10 day great per month average , Use ergotcontaining medication ten day great per month average , Use NSAIDs , acetaminophen , isometheptenecontaining agent 15 day great per month average , Use opioids 10 day great per month average , Use two medication 15 day great per month average , 5 . Patients clinically significant neurological illness , migraine , , opinion Investigators , may potential alter pain perception reporting , 6 . Patients history currently major psychiatric disorder include schizophrenia , major depressive disorder , bipolar disorder , 7 . Patients know positive hepatitis B surface antigen , hepatitis B core antibody , hepatitis C antibody , human immunodeficiency virus ( HIV ) , 8 . Patients elevation liver enzymes , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) &gt; = 1.5 time upper limit normal ( ULN ) , 9 . Patients evidence significant active hematological disease ; white blood cell count less equal 2500/uL absolute neutrophil count less equal 1000/uL , 10 . Patients clinically significant ECG abnormality , include prolonged QTc ( Fridericia correction ) define &gt; = 450 msec male &gt; = 470 msec female , 11 . Patients clinically significant active hepatic disease , cardiovascular , metabolic , respiratory , renal , endocrinological , gastrointestinal disease , bacterial viral infection within 30 day prior Screening Baseline Phase , 12 . Patients know suspected history alcoholism drug abuse within previous two year , positive finding urinary drug screen prescribed medication , 13 . Patients severe allergic reaction multiple drug , 14 . Patients condition would make , opinion PI , unsuitable study , 15 . Patients participate study involve administration investigational compound ( include E2007 ) within one month Visit 1 ( Screening ) , 16 . Patients know suspected allergy lactose , exclude lactose intolerance , 17 . Patients use follow medication medical reason study : betablockers , tricyclic antidepressant , antiepileptic , calcium channel blocker , monoamine oxidase inhibitor , NSAIDs daily , magnesium supplement high dos ( ie , 600 mg/day ) , riboflavin high dos ( ie , 100 mg/day ) , corticosteroid , local anesthetic , botuliunum toxin , herbal preparation feverfew St. John 's Wort . Patients use nonpharmacological prophylactic approach start least one month prior Screening may continue throughout study . 18 . ( revise per Amendment 03 ) 19 . Patients fail complete migraine diary adequately Baseline Phase ( ie , patient , complete diary entry least 21 day Baseline Phase ) . Randomized patient male female , 1865 year age , race , history migraine headache ( without aura accord Headache Classification Committee International Headache Society ( IHS , 2004 guideline ) least 12 month , onset age 50 , experience 412 migraine attack per month 3 month prior Screening Baseline Phase . Patients ' Body Mass Index ( BMI ) 19 40 kg/m2 inclusive Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>